目的 探讨降脂通便胶囊联合普伐他汀钠片治疗高脂血症的临床疗效。方法 选取2017年2月—2018年2月在邯郸市第二医院进行治疗的94例高脂血症患者作为研究对象，根据用药的差别将患者分为对照组（47例）和治疗组（47例）。对照组口服普伐他汀钠片，20 mg/次，1次/d；治疗组在对照组治疗的基础上口服降脂通便胶囊，2.0 g/次，2次/d。两组均连续治疗2个月。观察两组患者的临床疗效，比较两组患者治疗前后的血脂水平、炎性指标和肥胖指标水平。结果 治疗后，对照组总有效率为80.85%，显著低于治疗组的97.87%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）水平均明显降低，高密度脂蛋白胆固醇（HDL-C）水平明显增高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组血脂水平显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后两组血清超敏C反应蛋白（hs-CRP）、白细胞介素-1β（IL-1β）、干扰素-γ（IFN-γ）、肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组炎性指标水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组体质量（W）、肥胖度（A）、体质量指数（BMI）、体脂率（F）均明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组肥胖指标水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 降脂通便胶囊联合普伐他汀钠片治疗高脂血症可有效降低患者血脂和血清炎性因子水平，降低肥胖指标，具有较好的临床推广应用价值。

Objective To investigate the clinical efficacy of Jiangzhi Tongbian Capsules combined with Pravastatin Sodium Tablets in treatment of hyperlipidemia. Methods Patients (94 cases) with hyperlipidemia in Handan Second Hospital from February 2017 to February 2018 were randomly divided into control group (47 cases) and treatment group (47 cases), according to the difference of medication. Patients in the control group were po administered with Pravastatin Sodium Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Jiangzhi Tongbian Capsules on the basis of the control group, 2.0 g/time, twice daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the blood lipid, inflammatory markers, and obesity indexes levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.85%, which was significantly lower than 97.87% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the TC, TG, IL-4, and LDL-C levels in two groups were significantly decreased, but HDL-C level were increased, and the difference was statistically significant in the same group (P<0.05), and blood lipid levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, hs-CRP, IL-1β, IFN-γ, and TNF-α level in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And inflammatory markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, W, A, BMI, and F levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And obesity indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Jiangzhi Tongbian Capsules combined with Pravastatin Sodium Tablets in treatment of hyperlipidemia can effectively reduce the levels of blood lipid and serum inflammatory factors, and reduce obesity indexes, which has a certain clinical application value.

河北省卫生厅科技计划项目（20181661）